Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm
TDF/FTC adherence in the PrEPVacc trial was low, with considerable levels of white coat dosing. Inferring the counterfactual placebo HIV incidence using the estimated effectiveness of TDF/FTC is a promising approach, however, the approach requires further elaboration and evaluation.
Authors
- David Dunn (ORCID: https://orcid.org/0000-0003-1836-4446)
- Sheena Mc Cormack
- Henry Bern
- Julie Fox (ORCID: https://orcid.org/0000-0002-0583-8019)
- Eugene Ruzagira (ORCID: https://orcid.org/0000-0002-7291-1693)
- Christian Holm Hansen (ORCID: https://orcid.org/0000-0002-5949-0097)
- Sheila Kansiime (ORCID: https://orcid.org/0000-0003-3700-1501)
- Richard Hayes (ORCID: https://orcid.org/0000-0002-1729-9892)
Institutions
- University of London (GB)
- King's College London (GB)
- London School of Hygiene & Tropical Medicine (GB)
- Medical Research Council (GB)
- Uganda Virus Research Institute (UG)
Publication Details
- Journal
- HIV Research & Clinical Practice
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1080/25787489.2025.2513684
- Citations
- 1
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- United States Agency for International Development
- Gilead Sciences
- U.S. President’s Emergency Plan for AIDS Relief
- London School of Hygiene and Tropical Medicine
- Imperial College London
- European Commission
- South African Medical Research Council
- Karolinska Institutet
- Foreign, Commonwealth and Development Office
- Muhimbili University of Health and Allied Sciences
- University of Health and Allied Sciences
- Medical Research Council
- Walter Reed Army Institute of Research
- European and Developing Countries Clinical Trials Partnership